UY32091A - Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual - Google Patents

Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual

Info

Publication number
UY32091A
UY32091A UY0001032091A UY32091A UY32091A UY 32091 A UY32091 A UY 32091A UY 0001032091 A UY0001032091 A UY 0001032091A UY 32091 A UY32091 A UY 32091A UY 32091 A UY32091 A UY 32091A
Authority
UY
Uruguay
Prior art keywords
treatment
pharmaceutical composition
sexual transmission
infections
pharmaceutically acceptable
Prior art date
Application number
UY0001032091A
Other languages
English (en)
Inventor
Raul Garcia Salgado Lopez
Angelica Arzola Paniagua
Juan Pablo Senosiain Pelaz
Gustavo Brranco Hernandez
Original Assignee
Senosiain Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41796784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32091(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain Lab filed Critical Senosiain Lab
Publication of UY32091A publication Critical patent/UY32091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica oral sólida que comprende fluconazol, tinidazol y clindamicina o una sal farmacéuticamente aceptable de los mismos, donde el contenido de excipientes farmacéuticamente aceptables es significativamente menor que el contenido que los principios activos, el uso de dicha composición para la administración oral con actividad terapéutica para el tratamiento de infecciones de transmisión sexual.
UY0001032091A 2008-09-04 2009-09-04 Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual UY32091A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2008011321A MX2008011321A (es) 2008-09-04 2008-09-04 Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual.

Publications (1)

Publication Number Publication Date
UY32091A true UY32091A (es) 2010-02-26

Family

ID=41796784

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032091A UY32091A (es) 2008-09-04 2009-09-04 Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual

Country Status (13)

Country Link
US (1) US20110166087A1 (es)
EP (1) EP2329819B1 (es)
KR (1) KR101653424B1 (es)
BR (1) BRPI0918593B8 (es)
CA (1) CA2735926C (es)
CO (1) CO6321156A2 (es)
EC (1) ECSP11010941A (es)
ES (1) ES2734280T3 (es)
HN (1) HN2011000661A (es)
MX (1) MX2008011321A (es)
PE (1) PE20110448A1 (es)
UY (1) UY32091A (es)
WO (1) WO2010026469A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919742A (zh) * 2022-01-10 2023-04-07 江苏远恒药业有限公司 一种替硝唑栓的组合物及其制备方法与应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113768883A (zh) * 2021-08-25 2021-12-10 海南海神同洲制药有限公司 一种高稳定性盐酸克林霉素棕榈酸酯颗粒的制备方法
CN113768885A (zh) * 2021-09-16 2021-12-10 海南海神同洲制药有限公司 一种伏立康唑干混悬剂的制备工艺
CN116251067B (zh) * 2023-04-23 2024-06-07 淄博市中心医院 一种氟康唑片、制备方法及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094431B2 (en) 2000-10-12 2006-08-22 Mickey L. Peshoff Method of healing skin wounds in mammals and a composition therefor
MXPA02007641A (es) * 2002-08-08 2004-04-02 Alparis Sa De Cv Uso de farmaceutico de la combinacion de fluconazol-tinidazol y su composicion para la administracion oral.
US8309103B2 (en) * 2004-01-22 2012-11-13 Alparis, S.A. De C.V. Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage
CN101365425A (zh) * 2006-01-05 2009-02-11 药物技术公司 用于生物粘附到外阴阴道表面的递药系统
WO2008005783A2 (en) * 2006-06-30 2008-01-10 Drugtech Corporation Treatment of non- infectious inflammatory vulvovaginitis with a bioadhesive clindamycin composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919742A (zh) * 2022-01-10 2023-04-07 江苏远恒药业有限公司 一种替硝唑栓的组合物及其制备方法与应用

Also Published As

Publication number Publication date
EP2329819B1 (en) 2019-05-01
CA2735926C (en) 2016-09-06
CA2735926A1 (en) 2010-03-11
EP2329819A1 (en) 2011-06-08
KR101653424B1 (ko) 2016-09-01
BRPI0918593A2 (pt) 2018-05-22
ES2734280T3 (es) 2019-12-05
BRPI0918593A8 (pt) 2018-12-11
EP2329819A4 (en) 2011-09-14
HN2011000661A (es) 2013-09-16
BRPI0918593B1 (pt) 2020-11-10
BRPI0918593B8 (pt) 2021-05-25
WO2010026469A1 (es) 2010-03-11
CO6321156A2 (es) 2011-09-20
KR20110050678A (ko) 2011-05-16
PE20110448A1 (es) 2011-07-20
ECSP11010941A (es) 2011-06-30
US20110166087A1 (en) 2011-07-07
MX2008011321A (es) 2010-03-04

Similar Documents

Publication Publication Date Title
EA200870154A1 (ru) Лекарственное средство для местного применения
ES2553742T3 (es) Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
CL2012002126A1 (es) Composicion farmaceutica topica que comprende 1`-{[5-(trifluorometil)furan-2-il]metil}espiro[furo[2,3-f][1,3]benzodioxol-7,3`-indol]-2`(1`h)-ona; y uso para tratar, una enfermedad o condicion tal como dolor neuropatico, dolor quirurgico, dolor por trauma, dolor de cabeza cronico, entre otras.
AR048705A1 (es) Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
JP2010222367A5 (es)
MX2021000376A (es) Composiciones tópicas para el alivio del dolor.
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
MX2009011900A (es) Curacion de herida diabetica.
WO2011074015A3 (en) Composition of pharmaceutical product to treat sexual dysfunction
CO6321156A2 (es) Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
SE0950392L (sv) Sammansättning för behandling av hudåkommor
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
PE20120956A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
RU2011148355A (ru) Применение аллопуринола для ладонно-родошвенного синдрома
DOP2011000060A (es) Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
CR20110106A (es) Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20201223